Ractigen Therapeutics Funding: $80M Raised, Series A (2023)
Ractigen Therapeutics is based in Nantong, Jiangsu, China. It has raised $80M in total funding. Latest round: Series A.
Ractigen Therapeutics funding overview
Ractigen Therapeutics is based in Nantong, Jiangsu, China. Ractigen Therapeutics has raised $80M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in January 2023. The round record for Ractigen Therapeutics runs through 2023; nothing later has been disclosed. Investors on record include SDIC Venture Capital, Eisai Co., Ltd., LC Ventures, CSSD Capital, Xianghe Capital, Hillhouse Venture Capital and 3 others. 9 distinct backers are named across the disclosed rounds.
Frequently asked about Ractigen Therapeutics funding
How much has Ractigen Therapeutics raised?
Ractigen Therapeutics has raised $80M in total disclosed funding across the rounds on record.
Who has invested in Ractigen Therapeutics?
SDIC Venture Capital, Eisai Co., Ltd., LC Ventures, CSSD Capital, Xianghe Capital, Hillhouse Venture Capital are named among the investors backing Ractigen Therapeutics.
What was the latest Ractigen Therapeutics funding round?
The most recent disclosed round is a Series A, announced in January 2023.
Where is Ractigen Therapeutics based?
Ractigen Therapeutics is based in Nantong, Jiangsu, China.
When did Ractigen Therapeutics last raise?
The last disclosed Ractigen Therapeutics round closed in January 2023 at Series A.
We update the Ractigen Therapeutics record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Nantong and their backers are listed below.
